The Next Chapter of Renal Denervation After US Food and Drug Administration Approval.
- Resource Type
- Editorial & Opinion
- Authors
- Vongpatanasin W; Hypertension Section (W.V.), Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.; Cardiology Division (W.V., T.A.)., Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.; Addo T; Cardiology Division (W.V., T.A.)., Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
- Source
- Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4539 (Electronic) Linking ISSN: 00097322 NLM ISO Abbreviation: Circulation Subsets: MEDLINE
- Subject
- Language
- English
Competing Interests: Disclosures Dr Addo is Investigator for TARGET BP Trial of Renal Denervation by the Peregrine System (Ablative Solutions). Dr Vongpatanasin reports no conflict.